European Psychiatry - Volume 41 - April 2017

810 / 916

S806 25th European Congress of Psychiatry / European Psychiatry 41S (2017) S772–S846
with schizophrenia, were 3.6 for men and 4.3 for women. A recent
epidemiological study (2015) of a US-cohort of 1,138,853 individ-
uals with schizophrenia, 4,807,121 million years of follow-up and
74,003 deaths, all cause SMR was 3.7 for the total population: 3.3
for men and 4.3 for women. Life expectancy, the other side of the
coin of increased SMR, in this study was reduced with 28.5 years.
Studies in life expectancy, the other side of the coin of increased
SMR, show a substantial, if not alarming reduced life expectancy.
Israel with 12.5 years and Denmark–15 years for women and 20
years for men – reported the lowest reduction in life expectancy,
while Arizona reported the highest reduction of 32 years. Progress
in such diverse fields as genetics, neuro-imaging, early diagnosis of
(ultra) high-risk populations, CBT and rehabilitation treatment, has
not improved schizophrenia SMR or life expectancy. On the con-
trary, in far a trend is visible, the situation tends to worsen, not to
improve. After going through the barriers for optimal somatic care,
both patient and health care related, we will discuss options for
improvement of the level of somatic health care, at the preventive
and therapeutic level.
Disclosure of interest The author has not supplied his/her decla-
ration of competing interest.
EV1230
N-acetyl-cysteine in a double-blind
randomized placebo-controlled trial:
Towards biomarker guided treatment
in early psychosis
P. Conus ∗, M. Fournier , L. Xin , P. Baumann , C. Ferrari ,
A. Cousins , L. Alameda , P. Golay , R. Jenni , M.S. Kashavan ,
C.B. Eap , M. Cuenod , T. Buclin , R. Gruetter , L. Seidman ,
K.Q. Do
1 Lausanne University, Psychiatry, Prilly, Switzerland
2 CNP, Psychiatry, Lausanne, Switzerland
3 PGE, Psychiatry, Lausanne, Switzerland
4 Massachusetts Mental Health Center Public Psychiatry Division of
the Beth Israel Deaconess Medical Center, Department of Psychiatry,
Boston, MA, USA
5 PGE, Psychiatrie, Lausanne, Switzerland
6 CNP, Psychiatrie, Lausanne, Switzerland
7 Massachusetts Mental Health Center Public Psychiatry Division of
the Beth Israel Deaconess Medical Center, Harvard Medical School
Department of Psychiatry, Boston, MA, USA
8 Division of clinical Pharmacology, CHUV, Lausanne, Switzerland
9 Laboratory of Functional and Metabolic Imaging, Ecole
Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
10 CNP, Psychiatrie CHUV, Lausanne, Switzerland
∗ Corresponding author.
Purpose Recent evidence points to a critical role of redox dys-
regulation induced oxidative stress in the pathophysiology of
early phases of schizophrenia. An add-on trial with n-acetyl-
cysteine (NAC) led to a reduction in negative symptoms in chronic
schizophrenia patients. Aim of this study was to explore impact
of addition of NAC to standard treatment in early psychosis (EP)
patients.
Methods Double-blind, randomized, placebo-controlled trial of
addition of NAC, 2700mg daily, to antipsychotic treatment over 6
months. Monthly assessment of PANSS, GAF, SOFAS and antipsy-
chotics treatment; quantification of brain glutathione levels
(GSHmPFC) by 1H-magnetic-resonance-spectroscopy and of blood
cells glutathione (GSHBC) and glutathione peroxidase activity
(GPxBC) as marker of oxidation status at the beginning and end of
treatment.
Results Overall, 63 patients were included. Spectroscopy data
showed that GSHmPFC increased by +23% in the NAC group, while
it tended to decrease by −5% in the placebo group (P = 0.005).
No significant difference between NAC and placebo was observed
on global changes in negative symptoms, positive symptoms or
functional outcome. However, in patients with high-baseline oxi-
dation status (GPxBC>22.3U/gHb), subgroup explorations revealed
an improvement of positive symptoms over time compared to
patients with low-baseline GPx (P = 0.02).
Conclusions While addition of NAC induced an increase of brain
GSH, it had no impact on symptomatic and functional outcome in
EP patients. However, in patients with high oxidation status, addi-
tion of NAC leads to significantly greater improvement in positive
symptoms. Future studies on antioxidant interventions inEP should
consider biomarker-guided treatment.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1231
Peripersonal space and schizophrenia:
Looking for the self boundaries
M. Corbo ∗, G. Di Cosmo , F. Ferri , A. Salone , D. Carlesi ,
M. Centofanti , F. Cipollone , M. Costantini , G. Di Iorio ,
G. Martinotti , M. di Giannantonio
1 University “G. D’ Annunzio” Chieti, Neuroscience, imaging and
clinical science, Chieti, Italy
2 University of Essex, Centre for Brain Science- Department of
Psychology, Colchester, United Kingdom
3 ASL 02 Lanciano-Vasto-Chieti, Mental Health Department, Chieti,
Italy
∗ Corresponding author.
Introduction Peripersonal space has been defined as the area
immediately surrounding the body in which interactions with a
person or an object can occur. Larger peripersonal spacemay reflect
discomfort in close interpersonal situation or cognitive deficit. Indi-
viduals with schizophrenia aremore sensitive to social stimulation.
The capacity to provide accurate judgments of peripersonal space
boundaries depend on the capacity to create an organized and
structured mental representation that integrates signals from dif-
ferent sensory modalities and brain regions.
Objectives We conducted a study on personal space in patients
with schizophrenia using a paradigm that was not affected by emo-
tional and social interference.
Aims We aimed to investigate the characteristics of personal
space in patients with schizophrenia.
Methods We recruited 20 schizophrenic patients according to
DSM-V criterion and 20 healthy volunteers, matched by gender
and age. Schizophrenic symptoms were assessed using the Positive
and Negative Syndrome Scale (PANSS). Participants performed the
peripersonal space (PPS) task. Collected data underwent statistical
analyses.
Results Schizophrenic patients demonstrate a stronger/weaker
need for personal space, than the comparison group, depend-
ing on the score of negative and positive symptom, as
assessed by using the PANSS even without emotional and social
interference.
Conclusions Interpersonal interactions between the individual
with schizophrenia and people in their immediate environment
can lead to increased symptomatology. Social isolation is one of
the most primary causes of poor quality of life in mental illnesses.
Better understanding of the mechanisms for abnormal interactive
behavior could provide significant valid guidelines for innovating
intervention programs.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.